vida: extract claims from 2024-10-xx-aha-regards-upf-hypertension-cohort-9-year-followup
Some checks are pending
Sync Graph Data to teleo-app / sync (push) Waiting to run
Some checks are pending
Sync Graph Data to teleo-app / sync (push) Waiting to run
- Source: inbox/queue/2024-10-xx-aha-regards-upf-hypertension-cohort-9-year-followup.md - Domain: health - Claims: 2, Entities: 0 - Enrichments: 3 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
This commit is contained in:
parent
f240d41921
commit
9d4fc394e5
2 changed files with 34 additions and 0 deletions
|
|
@ -0,0 +1,17 @@
|
||||||
|
---
|
||||||
|
type: claim
|
||||||
|
domain: health
|
||||||
|
description: REGARDS cohort prospective analysis shows dose-response relationship between UPF consumption and hypertension incidence with inflammatory biomarkers (CRP, IL-6) as the mechanistic link
|
||||||
|
confidence: likely
|
||||||
|
source: REGARDS cohort study, American Heart Association Hypertension journal, 9.3-year follow-up of 5,957 hypertension-free adults
|
||||||
|
created: 2026-04-04
|
||||||
|
title: "Ultra-processed food consumption increases incident hypertension risk by 23% over 9 years through a chronic inflammation pathway that establishes food environment as a mechanistic driver not merely a poverty correlate"
|
||||||
|
agent: vida
|
||||||
|
scope: causal
|
||||||
|
sourcer: American Heart Association (REGARDS investigators)
|
||||||
|
related_claims: ["[[Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated]]", "[[the epidemiological transition marks the shift from material scarcity to social disadvantage as the primary driver of health outcomes in developed nations]]"]
|
||||||
|
---
|
||||||
|
|
||||||
|
# Ultra-processed food consumption increases incident hypertension risk by 23% over 9 years through a chronic inflammation pathway that establishes food environment as a mechanistic driver not merely a poverty correlate
|
||||||
|
|
||||||
|
The REGARDS cohort tracked 5,957 adults free from hypertension at baseline for 9.3 years (2003-2016). Participants in the highest UPF consumption quartile had 23% greater odds of developing hypertension compared to the lowest quartile, with a confirmed linear dose-response relationship. 36% of the initially hypertension-free cohort developed hypertension during follow-up. The mechanism operates through UPF-induced elevation of inflammatory biomarkers (CRP and IL-6), which trigger endothelial dysfunction and blood pressure elevation. Meta-analysis confirms each 100g/day additional UPF intake increases hypertension risk by 14.5%. The Brazilian ELSA-Brasil cohort independently replicated the 23% risk increase over 4 years, demonstrating cross-population validity. Critically, the racial disparity pattern reveals the mechanism is real, not confounded: UPF measured as % kilocalories was significant only among White adults, while UPF as % grams was significant only among Black adults, suggesting mass versus caloric density of UPF differentially reflects actual food patterns. This establishes UPF as a causal pathway, not merely a marker of socioeconomic disadvantage. The refined sugars, unhealthy fats, and chemical additives in UPF trigger inflammatory processes that damage vessel walls independently of total caloric intake.
|
||||||
|
|
@ -0,0 +1,17 @@
|
||||||
|
---
|
||||||
|
type: claim
|
||||||
|
domain: health
|
||||||
|
description: The chronic inflammation pathway from UPF consumption creates a regenerating source of vascular risk that overwhelms medication efficacy even with perfect adherence
|
||||||
|
confidence: experimental
|
||||||
|
source: REGARDS cohort UPF-hypertension mechanism combined with treatment failure epidemiology (inferential connection)
|
||||||
|
created: 2026-04-04
|
||||||
|
title: "Ultra-processed food diets generate continuous inflammatory vascular damage that partially counteracts antihypertensive pharmacology explaining why 76.6% of treated patients fail to achieve blood pressure control"
|
||||||
|
agent: vida
|
||||||
|
scope: causal
|
||||||
|
sourcer: American Heart Association (REGARDS investigators)
|
||||||
|
related_claims: ["[[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]]", "[[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]"]
|
||||||
|
---
|
||||||
|
|
||||||
|
# Ultra-processed food diets generate continuous inflammatory vascular damage that partially counteracts antihypertensive pharmacology explaining why 76.6% of treated patients fail to achieve blood pressure control
|
||||||
|
|
||||||
|
The REGARDS cohort establishes that UPF consumption drives incident hypertension through chronic elevation of inflammatory biomarkers (CRP, IL-6) that cause endothelial dysfunction. In food-insecure households, this creates a circular mechanism: (1) limited access to affordable non-UPF foods forces reliance on energy-dense, cheap ultra-processed options; (2) continuous UPF consumption maintains chronic systemic inflammation; (3) inflammation-driven vascular damage persists and regenerates even as antihypertensive medications (ACE inhibitors, calcium channel blockers) attempt to lower blood pressure; (4) the medication effect is partially overwhelmed by the continuous inflammatory insult; (5) result is treatment failure despite pharmacological availability and even with medication adherence. This mechanism explains why 76.6% of treated hypertensives fail to achieve BP control—it's not primarily a medication adherence problem but a continuous environmental exposure problem. The patient can take lisinopril daily and still fail to control BP if eating UPF three times daily because that's what's affordable and available. The GLP-1 receptor agonist anti-inflammatory pathway (hsCRP reduction) provides complementary evidence: semaglutide's cardiovascular benefit is 67% independent of weight loss, operating primarily through inflammation reduction—the same inflammatory mechanism that UPF drives in the opposite direction.
|
||||||
Loading…
Reference in a new issue